多西拉敏
參見

1 2 3  Pelser A, Müller DG, du Plessis J, du Preez JL, Goosen C. . Biopharmaceutics & Drug Disposition. September 2002, 23 (6): 239–244. PMID 12214324. S2CID 32126626. doi:10.1002/bdd.314.
1 2 3 4 5 6 7  Kryger MH, Roth T, Dement WC. . Elsevier Health Sciences. 2010-11-01: 925. ISBN 978-1-4377-2773-9.
1 2 3  Allison M, Hale C. . Drugs in R&D. June 2018, 18 (2): 129–136. PMC 5995792 . PMID 29671128. doi:10.1007/s40268-018-0232-1.
1 2 3 4 5  Culpepper L, Wingertzahn MA. . The Primary Care Companion for CNS Disorders. 2015, 17 (6). PMC 4805417 . PMID 27057416. doi:10.4088/PCC.15r01798.
1 2 3   (PDF). Medsafe, New Zealand Medicines and Medical Devices Safety Authority. 2008-07-16. （原始内容存档于2016-03-22）.
1 2 3  Neubauer DN. . Journal of Clinical Sleep Medicine. August 2007, 3 (5 Suppl): S11–S15. PMC 1978321 . PMID 17824496. doi:10.5664/jcsm.26930.
1 2  Fischer J, Ganellin CR. . John Wiley & Sons. 2006: 546. ISBN 9783527607495.
1 2 3 4  Simons FE, Simons KJ. . The Journal of Allergy and Clinical Immunology. December 2011, 128 (6): 1139–1150.e4. PMID 22035879. doi:10.1016/j.jaci.2011.09.005 .
↑  .
↑  .   [2024-02-16]. （原始内容存档于2020-03-21）.
↑  Ringdahl EN, Pereira SL, Delzell JE. . The Journal of the American Board of Family Practice. 2004, 17 (3): 212–219. PMID 15226287. doi:10.3122/jabfm.17.3.212 .
1 2  Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. . Journal of Clinical Sleep Medicine. October 2008, 4 (5): 487–504. PMC 2576317 . PMID 18853708. doi:10.5664/jcsm.27286.
1 2  Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. . Journal of Clinical Sleep Medicine. February 2017, 13 (2): 307–349. PMC 5263087 . PMID 27998379. doi:10.5664/jcsm.6470.
1 2 3 4  De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N,  et al. . Lancet. July 2022, 400 (10347): 170–184. PMID 35843245. S2CID 250536370. doi:10.1016/S0140-6736(22)00878-9 .
↑  Perry PJ. . Lippincott Williams & Wilkins. 2007. ISBN 9780781762731.
↑  Dupuis G, Vaugeois JM.  [The interesting anti-H1 effects in maintenance insomnia: A reflection on the comparative advantages of doxylamine and doxepin]. L'Encephale. February 2020, 46 (1): 80–82. PMID 30879783. S2CID 151085176. doi:10.1016/j.encep.2019.01.006  （法语）.
↑  Lie JD, Tu KN, Shen DD, Wong BM. . P & T. November 2015, 40 (11): 759–771. PMC 4634348 . PMID 26609210.
1 2 3 4  Shirley DW, Sterrett J, Haga N, Durham C. . The Nurse Practitioner. February 2020, 45 (2): 8–21. PMID 31913218. S2CID 210086511. doi:10.1097/01.NPR.0000651112.76528.ed .
1 2 3 4 5  Nuangchamnong N, Niebyl J. . International Journal of Women's Health. 2014, 6: 401–409. PMC 3990370 . PMID 24748822. doi:10.2147/IJWH.S46653 .
1 2 3 4 5  Madjunkova S, Maltepe C, Koren G. . Paediatric Drugs. June 2014, 16 (3): 199–211. PMC 4030125 . PMID 24574047. doi:10.1007/s40272-014-0065-5.
↑  Cada DJ, Demaris K, Levien TL, Baker DE. . Hospital Pharmacy. October 2013, 48 (9): 762–766. PMC 3857125 . PMID 24421551. doi:10.1310/hpj4809-762.
1 2 3 4 5  . accessdata.fda.gov.   [2022-08-23]. （原始内容存档于2017-11-02）.
↑  . DailyMed. U.S. National Library of Medicine.   [2024-02-16]. （原始内容存档于2024-02-22）.
↑  .   [2024-02-16]. （原始内容存档于2015-02-28）.
↑  Briggs GG, Freeman RK, Yaffe SJ. . Obstetric Medicine 2. Lippincott Williams & Wilkins. 2008: 89. ISBN 978-0-7817-7876-3. PMC 4989726 . doi:10.1258/om.2009.090002.  |issue=被忽略 (帮助)
↑  Avidan AY. . Elsevier Health Sciences. 2017: 394  [2024-02-16]. ISBN 978-0-323-47349-1. （原始内容存档于2023-01-14）.
↑  Rutter P, Newby D. . Elsevier Health Sciences. 2015-09-11: 99  [2024-02-16]. ISBN 978-0-7295-8345-9. （原始内容存档于2023-01-14）.
↑  Stahl SM. . CNS Spectrums. December 2008, 13 (12): 1027–1038. PMID 19179941. S2CID 6849261. doi:10.1017/s1092852900017089.
↑  Doxylamine succinate (CAS 562-10-7) 的存檔，存档日期2012-05-01.. berkeley.edu.
↑  DOXYLAMINE SUCCINATE （页面存档备份，存于）. International Agency for Research on Cancer (IARC) – Summaries & Evaluations.
↑  Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R,  et al. . JAMA Internal Medicine. March 2015, 175 (3): 401–407. PMC 4358759 . PMID 25621434. doi:10.1001/jamainternmed.2014.7663.
↑  Carrière I, Fourrier-Reglat A, Dartigues JF, Rouaud O, Pasquier F, Ritchie K, Ancelin ML. . Archives of Internal Medicine. July 2009, 169 (14): 1317–1324. PMC 2933398 . PMID 19636034. doi:10.1001/archinternmed.2009.229.
↑  . Office of the Federal Register, National Archives and Records Service, General Services Administration. 1978: 25584  [2024-02-16]. OCLC 1768512. （原始内容存档于2023-04-04）.
↑  . hazard.com. 原始内容存档于2022-01-17.
↑  Syed H, Som S, Khan N, Faltas W. . BMJ Case Reports. 17 March 2009, 2009 (90): 845. PMC 3028279 . PMID 21686586. doi:10.1136/bcr.09.2008.0879.
↑  Leybishkis B, Fasseas P, Ryan KF. . The American Journal of the Medical Sciences. July 2001, 322 (1): 48–49. PMID 11465247. doi:10.1097/00000441-200107000-00009.
↑  Roth BL, Driscol J. . Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health.   [2017-08-14]. （原始内容存档于2019-06-12）.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  Krystal AD, Richelson E, Roth T. . Sleep Medicine Reviews. August 2013, 17 (4): 263–272. PMID 23357028. doi:10.1016/j.smrv.2012.08.001.
1 2 3 4  Vande Griend JP, Anderson SL. . Journal of the American Pharmacists Association. 2012, 52 (6): e210–e219. PMID 23229983. doi:10.1331/JAPhA.2012.12051.
↑  Krystal AD. . Sleep Medicine Reviews. August 2009, 13 (4): 265–274. PMID 19153052. doi:10.1016/j.smrv.2008.08.001.
↑  Holder CL, Korfmacher WA, Slikker W, Thompson HC, Gosnell AB. . Biomedical Mass Spectrometry. April 1985, 12 (4): 151–158  [2024-02-16]. PMID 2861861. S2CID 6020605. doi:10.1002/bms.1200120403. （原始内容存档于2021-05-12）.
↑  Kalpaklioglu F, Baccioglu A. . Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry. 2012, 11 (3): 230–237. PMID 23173575. doi:10.2174/1871523011202030230.
1 2  Atta-ur-Rahman (编). . Bentham Science Publishers. 11 July 2018: 30  [2024-02-16]. ISBN 978-1-68108-337-7. OCLC 1048922805. （原始内容存档于2023-04-04）.
↑  Sperber N, Papa D. . Journal of the American Chemical Society. March 1949, 71 (3): 887–890. PMID 18113525. doi:10.1021/ja01171a034.
1 2 3  Briggs GG, Freeman RK, Yaffe SJ.  9. Lippincott Williams & Wilkins. 28 March 2012: 453  [2024-02-16]. ISBN 978-1-4511-5359-0. OCLC 1232803849. （原始内容存档于2023-04-03）.
↑  Slaughter SR, Hearns-Stokes R, van der Vlugt T, Joffe HV. . The New England Journal of Medicine. March 2014, 370 (12): 1081–1083. PMID 24645939. doi:10.1056/NEJMp1316042 .
一位健康的志願者於口服一顆23毫克的多西拉敏藥丸後的血藥濃度隨時間的變化。X軸顯示的是服用之後的小時數。